Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | AHR | P35869 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19308895 | 0.92 | EIF4A3 (0.43) | KDM4EALDH1A1PDE2AEIF4A3ACACB | |
| SCHEMBL21524642 | 0.91 | EIF4A3 (0.42) | KDM4EALDH1A1EIF4A3SLC6A2SLC6A4 | |
| SCHEMBL20004036 | 0.89 | LOXL2 (0.47) | KDM4EALDH1A1PDE2AACACBMEN1 | |
| SCHEMBL25085612 | 0.81 | BACE1 (0.42) | KDM4EALDH1A1PDE2AACACBMEN1 | |
| SCHEMBL20004019 | 0.80 | DAO (0.39) | PDE2AACACBMEN1POLBMAPK1 | |
| SCHEMBL83970 | 0.78 | AHR (0.50) | KDM4EALDH1A1PDE2AEIF4A3MEN1 | |
| SCHEMBL19440374 | 0.78 | KIF11 (0.35) | KDM4EALDH1A1PDE2AACACBMEN1 | |
| SCHEMBL19120145 | 0.78 | IDH1 (0.35) | MAPTTHRBLOXL2 | |
| SCHEMBL21323218 | 0.75 | DAO (0.40) | KDM4EALDH1A1PDE2AACACBBACE1 | |
| SCHEMBL24478695 | 0.74 | EIF4A3 (0.39) | EIF4A3MAPTTHRBKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021194959-A1 | TREATMENT OF EYE DISORDERS WITH URIDINE PHOSPHATE DERIVATIVES | GLIAGUARD, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-11124536-B2 | Uridine nucleoside derivatives, compositions and methods of use | TUFTS UNIVERSITY (US) | 2021-09-21 | — | — | US | disclosed |
| US-11072627-B2 | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders | TUFTS UNIVERSITY (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200399302-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-10632138-B2 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | TUFTS UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190309009-A1 | URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | TUFTS UNIVERSITY | 2019-10-10 | — | — | US | disclosed |
| US-9913855-B2 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | TUFTS UNIVERSITY (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124536-B2 | Uridine nucleoside derivatives, compositions and methods of use | P2RY6, UPP1, UMPS | KDM4E 4743/4885ALDH1A1 2982/4885PDE2A 250/4885 |
| US-20190309009-A1 | URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | P2RY6, P2RX6, P2RY1 | KDM4E 4387/4885ALDH1A1 1437/4885PDE2A 709/4885 |
| US-20200399302-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | KDM4E 4743/4885ALDH1A1 2982/4885PDE2A 250/4885 |
| US-11072627-B2 | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders | P2RY6, P2RX6, P2RY1 | KDM4E 4335/4885ALDH1A1 1209/4885PDE2A 731/4885 |
| US-10632138-B2 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | UMPS, UPP1, UGDH | KDM4E 4085/4885ALDH1A1 1514/4885PDE2A 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.